Cellular transcription factor Oct-1 interacts with the Epstein-Barr virus BRLF1 protein to promote disruption of viral latency

Journal of Virology

Volumn 85, Issue 17, 2011, Pages 8940-8953

  Robinson, Amanda R ^a,b   Kwek, Swee Sen ^a   Hagemeier, Stacy R ^a   Wille, Coral K ^a,b   Kenney, Shannon C ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMEDIATE EARLY PROTEIN; IMMEDIATE EARLY PROTEIN BHLF1; IMMEDIATE EARLY PROTEIN BHRF1; IMMEDIATE EARLY PROTEIN BMRF1; IMMEDIATE EARLY PROTEIN BRLF1; IMMEDIATE EARLY PROTEIN BZLF1; METHIONINE; OCTAMER TRANSCRIPTION FACTOR 1; PROTEIN SM; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA BINDING; EPITHELIUM CELL; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; VIRUS LATENCY; VIRUS REACTIVATION;

AMINO ACID SUBSTITUTION; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; DNA, VIRAL; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMEDIATE-EARLY PROTEINS; MUTANT PROTEINS; MUTATION, MISSENSE; OCTAMER TRANSCRIPTION FACTOR-1; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; TRANS-ACTIVATORS; VIRUS ACTIVATION; VIRUS LATENCY;

HUMAN HERPESVIRUS 4;

EID: 80052286938     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00569-11     Document Type: Article

References (101)

1. Adamson, A. L., et al. 2000. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J. Virol. 74:1224-1233.
2. Adamson, A. L., and S. C. Kenney. 1998. Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product. Virology 251:187-197.
3. Almqvist, J., et al. 2005. Functional interaction of Oct transcription factors with the family of repeats in Epstein-Barr virus oriP. J. Gen. Virol. 86:1261-1267.
4. Bhende, P. M., S. J. Dickerson, X. Sun, W. H. Feng, and S. C. Kenney. 2007. X-box-binding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D. J. Virol. 81:7363-7370.
5. Bhende, P. M., W. T. Seaman, H. J. Delecluse, and S. C. Kenney. 2005. BZLF1 activation of the methylated form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186. J. Virol. 79:7338-7348.
6. Bowser, B. S., S. Morris, M. J. Song, R. Sun, and B. Damania. 2006. Characterization of Kaposi's sarcoma-associated herpesvirus (KSHV) K1 promoter activation by Rta. Virology 348:309-327.
7. Carroll, K. D., F. Khadim, S. Spadavecchia, D. Palmeri, and D. M. Lukac. 2007. Direct interactions of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50/Rta protein with the cellular protein octamer-1 and DNA are critical for specifying transactivation of a delayed-early promoter and stimulating viral reactivation. J. Virol. 81:8451-8467.
8. Cepek, K. L., D. I. Chasman, and P. A. Sharp. 1996. Sequence-specific DNA binding of the B-cell-specific coactivator OCA-B. Genes Dev. 10:2079-2088.
9. Chang, L. K., J. Y. Chuang, M. Nakao, and S. T. Liu. 2010. MCAF1 and synergistic activation of the transcription of Epstein-Barr virus lytic genes by Rta and Zta. Nucleic Acids Res. 38:4687-4700.
10. Chang, L. K., et al. 2005. Activation of Sp1-mediated transcription by Rta of Epstein-Barr virus via an interaction with MCAF1. Nucleic Acids Res. 33:6528-6539.
11. Chang, P. J., et al. 2002. Open reading frame 50 protein of Kaposi's sarcoma-associated herpesvirus directly activates the viral PAN and K12 genes by binding to related response elements. J. Virol. 76:3168-3178.
12. Chen, L. W., P. J. Chang, H. J. Delecluse, and G. Miller. 2005. Marked variation in response of consensus binding elements for the Rta protein of Epstein-Barr virus. J. Virol. 79:9635-9650.
13. Chevallier-Greco, A., et al. 1986. Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J. 5:3243-3249.
14. Countryman, J., H. Jenson, R. Seibl, H. Wolf, and G. Miller. 1987. Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J. Virol. 61:3672-3679.
15. Countryman, J., and G. Miller. 1985. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. U. S. A. 82:4085-4089.
16. Cox, M. A., J. Leahy, and J. M. Hardwick. 1990. An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators. J. Virol. 64:313-321.
17. Darr, C. D., A. Mauser, and S. Kenney. 2001. Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J. Virol. 75:6135-6142.
18. Delecluse, H. J., T. Hilsendegen, D. Pich, R. Zeidler, and W. Hammerschmidt. 1998. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc. Natl. Acad. Sci. U. S. A. 95:8245-8250.
19. Deng, H., M. J. Song, J. T. Chu, and R. Sun. 2002. Transcriptional regulation of the interleukin-6 gene of human herpesvirus 8 (Kaposi's sarcomaassociated herpesvirus). J. Virol. 76:8252-8264.
20. Di Bartolo, D. L., et al. 2009. Role of defective Oct-2 and OCA-B expression in immunoglobulin production and Kaposi's sarcoma-associated herpesvirus lytic reactivation in primary effusion lymphoma. J. Virol. 83:4308-4315.
21. Duan, W., S. Wang, S. Liu, and C. Wood. 2001. Characterization of Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 ORF57 promoter. Arch. Virol. 146:403-413.
22. Fan, W., et al. 2002. BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs. J. Biol. Chem. 277:8061-8067.
23. Farrell, P. J., D. T. Rowe, C. M. Rooney, and T. Kouzarides. 1989. Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J. 8:127-132.
24. Feederle, R., et al. 2000. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 19:3080-3089.
25. Feng, W. H., B. Israel, N. Raab-Traub, P. Busson, and S. C. Kenney. 2002. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res. 62:1920-1926.
26. Flemington, E., and S. H. Speck. 1990. Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J. Virol. 64:1227-1232.
27. Gallo, G. J., M. C. Gruda, J. R. Manuppello, and J. C. Alwine. 1990. Activity of simian DNA-binding factors is altered in the presence of simian virus 40 (SV40) early proteins: characterization of factors binding to elements involved in activation of the SV40 late promoter. J. Virol. 64:173-184.
28. Gruffat, H., et al. 1992. Characterization of an R-binding site mediating the R-induced activation of the Epstein-Barr virus BMLF1 promoter. J. Virol. 66:46-52.
29. Gruffat, H., E. Manet, A. Rigolet, and A. Sergeant. 1990. The enhancer factor R of Epstein-Barr virus (EBV) is a sequence-specific DNA binding protein. Nucleic Acids Res. 18:6835-6843.
30. Gruffat, H., and A. Sergeant. 1994. Characterization of the DNA-binding site repertoire for the Epstein-Barr virus transcription factor R. Nucleic Acids Res. 22:1172-1178.
31. Hardwick, J. M., P. M. Lieberman, and S. D. Hayward. 1988. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J. Virol. 62:2274-2284.
32. Hayward, S. D. 2004. Viral interactions with the Notch pathway. Semin. Cancer Biol. 14:387-396.
33. Henkel, T., P. D. Ling, S. D. Hayward, and M. G. Peterson. 1994. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science 265:92-95.
34. Herr, W. 1998. The herpes simplex virus VP16-induced complex: mechanisms of combinatorial transcriptional regulation. Cold Spring Harb. Symp. Quant. Biol. 63:599-607.
35. Hong, G. K., et al. 2004. The BRRF1 early gene of Epstein-Barr virus encodes a transcription factor that enhances induction of lytic infection by BRLF1. J. Virol. 78:4983-4992.
36. Jiang, Y., D. Xu, Y. Zhao, and L. Zhang. 2008. Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma. PLoS One 3:e1569.
37. Johannsen, E., et al. 1995. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J. Virol. 69:253-262.
38. Kang, J., et al. 2009. A general mechanism for transcription regulation by Oct1 and Oct4 in response to genotoxic and oxidative stress. Genes Dev. 23:208-222.
39. Kang, J., A. Shakya, and D. Tantin. 2009. Stem cells, stress, metabolism and cancer: a drama in two Octs. Trends Biochem. Sci. 34:491-499.
40. Kenney, S., E. Holley-Guthrie, E. C. Mar, and M. Smith. 1989. The Ep-stein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators. J. Virol. 63:3878-3883.
41. Kenney, S., et al. 1989. The Epstein-Barr virus (EBV) BZLF1 immediateearly gene product differentially affects latent versus productive EBV promoters. J. Virol. 63:1729-1736.
42. Kieff, E., and A. B. Rickinson. 2007. Epstein-Barr virus and its replication, p. 2603-2654. In D. M. Knipe et al. (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
43. Kim, U., et al. 1996. The B-cell-specific transcription coactivator OCA-B/OBF-1/Bob-1 is essential for normal production of immunoglobulin isotypes. Nature 383:542-547.
44. Kossakowska, A. E., and S. J. Urbanski. 1991. Differentiation of human B-cell malignant lymphomas is independent of the octamer lymphoid specific binding factor (Oct-2). Immunology 74:37-43.
45. Kristie, T. M., and P. A. Sharp. 1990. Interactions of the Oct-1 POU subdomains with specific DNA sequences and with the HSV alpha-transactivator protein. Genes Dev. 4:2383-2396.
46. Kristie, T. M., and P. A. Sharp. 1993. Purification of the cellular C1 factor required for the stable recognition of the Oct-1 homeodomain by the herpes simplex virus alpha-trans-induction factor (VP16). J. Biol. Chem. 268:6525-6534.
47. Latchman, D. S. 1996. The Oct-2 transcription factor. Int. J. Biochem. Cell Biol. 28:1081-1083.
48. Lee, Y. H., Y. F. Chiu, W. H. Wang, L. K. Chang, and S. T. Liu. 2008. Activation of the ERK signal transduction pathway by Epstein-Barr virus immediate-early protein Rta. J. Gen. Virol. 89:2437-2446.
49. Liang, Y., J. Chang, S. J. Lynch, D. M. Lukac, and D. Ganem. 2002. The lytic switch protein of KSHV activates gene expression via functional interaction with RBP-Jkappa (CSL), the target of the Notch signaling pathway. Genes Dev. 16:1977-1989.
50. Lieberman, P. M., J. M. Hardwick, J. Sample, G. S. Hayward, and S. D. Hayward. 1990. The zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions. J. Virol. 64:1143-1155.
51. Liu, P., and S. H. Speck. 2003. Synergistic autoactivation of the Epstein-Barr virus immediate-early BRLF1 promoter by Rta and Zta. Virology 310:199-206.
52. Lukac, D. M., L. Garibyan, J. R. Kirshner, D. Palmeri, and D. Ganem. 2001. DNA binding by Kaposi's sarcoma-associated herpesvirus lytic switch protein is necessary for transcriptional activation of two viral delayed early promoters. J. Virol. 75:6786-6799.
53. Lukac, D. M., J. R. Kirshner, and D. Ganem. 1999. Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells. J. Virol. 73:9348-9361.
54. Lukac, D. M., R. Renne, J. R. Kirshner, and D. Ganem. 1998. Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology 252:304-312.
55. Malin, S., et al. 2005. DNA-dependent conversion of Oct-1 and Oct-2 into transcriptional repressors by Groucho/TLE. Nucleic Acids Res. 33:4618-4625.
56. Manet, E., A. Rigolet, H. Gruffat, J. F. Giot, and A. Sergeant. 1991. Domains of the Epstein-Barr virus (EBV) transcription factor R required for dimerization, DNA binding and activation. Nucleic Acids Res. 19:2661-2667.
57. Meng, Q., S. R. Hagemeier, C. V. Kuny, R. F. Kalejta, and S. C. Kenney. 2010. Simian virus 40 T/t antigens and lamin A/C small interfering RNA rescue the phenotype of an Epstein-Barr virus protein kinase (BGLF4)mutant. J. Virol. 84:4524-4533.
58. Moriuchi, H., M. Moriuchi, and J. I. Cohen. 1995. Proteins and cis-acting elements associated with transactivation of the varicella-zoster virus (VZV) immediate-early gene 62 promoter by VZV open reading frame 10 protein. J. Virol. 69:4693-4701.
59. Narayanan, A., M. L. Nogueira, W. T. Ruyechan, and T. M. Kristie. 2005. Combinatorial transcription of herpes simplex virus and varicella zoster virus immediate early genes is strictly determined by the cellular coactivator HCF-1. J. Biol. Chem. 280:1369-1375.
60. Persson, L. M., and A. C. Wilson. 2010. Wide-scale use of Notch signaling factor CSL/RBP-Jkappa in RTA-mediated activation of Kaposi's sarcomaassociated herpesvirus lytic genes. J. Virol. 84:1334-1347.
61. Phillips, K., and B. Luisi. 2000. The virtuoso of versatility: POU proteins that flex to fit. J. Mol. Biol. 302:1023-1039.
62. Quinlivan, E. B., et al. 1993. Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res. 21:1999-2007.
63. Ragoczy, T., L. Heston, and G. Miller. 1998. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J. Virol. 72:7978-7984.
64. Ragoczy, T., and G. Miller. 2001. Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites. J. Virol. 75:5240-5251.
65. Rhee, J. M., M. Trieu, and E. E. Turner. 2001. Optimal Oct-2 affinity for an extended DNA site and the effect of GST fusion on site preference. Arch. Biochem. Biophys. 385:397-405.
66. Rickinson, A. B., and E. Kieff. 2007. Epstein-Barr virus, p. 2655-2700. In D. M. Knipe et al. (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
67. Robertson, E. S., et al. 1995. Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNAbinding protein J kappa. J. Virol. 69:3108-3116.
68. Rooney, C. M., D. T. Rowe, T. Ragot, and P. J. Farrell. 1989. The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J. Virol. 63:3109-3116.
69. Ryan, A. K., and M. G. Rosenfeld. 1997. POU domain family values: flexibility, partnerships, and developmental codes. Genes Dev. 11:1207-1225.
70. Sakakibara, S., K. Ueda, J. Chen, T. Okuno, and K. Yamanishi. 2001. Octamer-binding sequence is a key element for the autoregulation of Kaposi's sarcoma-associated herpesvirus ORF50/Lyta gene expression. J. Virol. 75:6894-6900.
71. Schild-Poulter, C., et al. 2007. DNA-PK phosphorylation sites on Oct-1 promote cell survival following DNA damage. Oncogene 26:3980-3988.
72. Schild-Poulter, C., A. Shih, N. C. Yarymowich, and R. J. Haché. 2003. Down-regulation of histone H2B by DNA-dependent protein kinase in response to DNA damage through modulation of octamer transcription factor 1. Cancer Res. 63:7197-7205.
73. Seaman, W. T., et al. 1999. Gene expression from the ORF50/K8 region of Kaposi's sarcoma-associated herpesvirus. Virology 263:436-449.
74. Shakya, A., J. Kang, J. Chumley, M. A. Williams, and D. Tantin. 2011. Oct1 is a switchable, bipotential stabilizer of repressed and inducible transcriptional states. J. Biol. Chem. 286:450-459.
75. Smith, G. A., and L. W. Enquist. 2000. A self-recombining bacterial artificial chromosome and its application for analysis of herpesvirus pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 97:4873-4878.
76. Song, M. J., X. Li, H. J. Brown, and R. Sun. 2002. Characterization of interactions between RTA and the promoter of polyadenylated nuclear RNA in Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. J. Virol. 76:5000-5013.
77. Souza, T. A., B. D. Stollar, J. L. Sullivan, K. Luzuriaga, and D. A. Thorley-Lawson. 2005. Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells. Proc. Natl. Acad. Sci. U. S. A. 102:18093-18098.
78. Staudt, L. M., et al. 1986. A lymphoid-specific protein binding to the octamer motif of immunoglobulin genes. Nature 323:640-643.
79. Staudt, M. R., and D. P. Dittmer. 2007. The Rta/Orf50 transactivator proteins of the gamma-herpesviridae. Curr. Top. Microbiol. Immunol. 312:71-100.
80. Strobl, L. J., et al. 1997. Both Epstein-Barr viral nuclear antigen 2 (EBNA2) and activated Notch1 transactivate genes by interacting with the cellular protein RBP-J kappa. Immunobiology 198:299-306.
81. Sun, R., et al. 1998. A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc. Natl. Acad. Sci. U. S. A. 95:10866-10871.
82. Swenson, J. J., E. Holley-Guthrie, and S. C. Kenney. 2001. Epstein-Barr virus immediate-early protein BRLF1 interacts with CBP, promoting enhanced BRLF1 transactivation. J. Virol. 75:6228-6234.
83. Takada, K., N. Shimizu, S. Sakuma, and Y. Ono. 1986. trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J. Virol. 57:1016-1022.
84. Tanaka, M., and W. Herr. 1990. Differential transcriptional activation by Oct-1 and Oct-2: interdependent activation domains induce Oct-2 phosphorylation. Cell 60:375-386.
85. Tantin, D., C. Schild-Poulter, V. Wang, R. J. Haché, and P. A. Sharp. 2005. The octamer binding transcription factor Oct-1 is a stress sensor. Cancer Res. 65:10750-10758.
86. Wang, S., S. Liu, M. Wu, Y. Geng, and C. Wood. 2001. Kaposi's sarcomaassociated herpesvirus/human herpesvirus-8 ORF50 gene product contains a potent C-terminal activation domain which activates gene expression via a specific target sequence. Arch. Virol. 146:1415-1426.
87. Wang, S. E., et al. 2004. Early activation of the Kaposi's sarcoma-associated herpesvirus RTA, RAP, and MTA promoters by the tetradecanoyl phorbol acetate-induced AP1 pathway. J. Virol. 78:4248-4267.
88. Wang, S. E., et al. 2003. Role of CCAAT/enhancer-binding protein alpha (C/EBPalpha) in activation of the Kaposi's sarcoma-associated herpesvirus (KSHV) lytic-cycle replication-associated protein (RAP) promoter in cooperation with the KSHV replication and transcription activator (RTA) and RAP. J. Virol. 77:600-623.
89. Welter, J. F., H. Gali, J. F. Crish, and R. L. Eckert. 1996. Regulation of human involucrin promoter activity by POU domain proteins. J. Biol. Chem. 271:14727-14733.
90. Werner, M., I. Ernberg, J. Zou, J. Almqvist, and E. Aurell. 2007. Epstein-Barr virus latency switch in human B-cells: a physico-chemical model. BMC Syst. Biol. 1:40.
91. Westphal, E. M., W. Blackstock, W. Feng, B. Israel, and S. C. Kenney. 2000. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBVpositive malignancies. Cancer Res. 60:5781-5788.
92. Wirth, T., P. Pfisterer, A. Annweiler, S. Zwilling, and H. König. 1995. Molecular principles of Oct2-mediated gene activation in B cells. Immunobiology 193:161-170.
93. Wysocka, J., and W. Herr. 2003. The herpes simplex virus VP16-induced complex: the makings of a regulatory switch. Trends Biochem. Sci. 28:294-304.
94. Xu, Y., et al. 2005. A Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50 deletion mutant is defective for reactivation of latent virus and DNA replication. J. Virol. 79:3479-3487.
95. Yu, X., Z. Wang, and J. E. Mertz. 2007. ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus. PLoS Pathog. 3:e194.
96. Zalani, S., E. Holley-Guthrie, and S. Kenney. 1996. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cellspecific mechanism. Proc. Natl. Acad. Sci. U. S. A. 93:9194-9199.
97. Zalani, S., E. A. Holley-Guthrie, D. E. Gutsch, and S. C. Kenney. 1992. The Epstein-Barr virus immediate-early promoter BRLF1 can be activated by the cellular Sp1 transcription factor. J. Virol. 66:7282-7292.
98. Zhang, L., J. Chiu, and J. C. Lin. 1998. Activation of human herpesvirus 8 (HHV-8) thymidine kinase (TK) TATAA-less promoter by HHV-8 ORF50 gene product is SP1 dependent. DNA Cell Biol. 17:735-742.
99. Zhao, H., et al. 2000. Activation of the transcription factor Oct-1 in response to DNA damage. Cancer Res. 60:6276-6280.
100. Zhu, J., et al. 2004. Effective inhibition of Rta expression and lytic replication of Kaposi's sarcoma-associated herpesvirus by human RNase P. Proc. Natl. Acad. Sci. U. S. A. 101:9073-9078.
101. zur Hausen, H., et al. 1970. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228:1056-1058.